Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonneveld, Pieter, Chanan-Khan, Asher, Weisel, Katja, Nooka, Ajay K., Masszi, Tamas, Beksac, Meral, Spicka, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria-Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Spencer, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022857/
https://www.ncbi.nlm.nih.gov/pubmed/36413710
http://dx.doi.org/10.1200/JCO.21.02734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022857/
https://www.ncbi.nlm.nih.gov/pubmed/36413710
http://dx.doi.org/10.1200/JCO.21.02734

Ejemplares similares